234 related articles for article (PubMed ID: 18828924)
1. Novel therapies in breast cancer: what is new from ASCO 2008.
Chu D; Lu J
J Hematol Oncol; 2008 Oct; 1():16. PubMed ID: 18828924
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. [Current status of treatment for early-stage invasive breast cancer].
Kásler M; Polgár C; Fodor J
Orv Hetil; 2009 May; 150(22):1013-21. PubMed ID: 19465349
[TBL] [Abstract][Full Text] [Related]
4. Protein Kinase Targets in Breast Cancer.
García-Aranda M; Redondo M
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186886
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs in metastatic breast cancer.
Dizdar O; Altundag K
Expert Opin Emerg Drugs; 2009 Mar; 14(1):85-98. PubMed ID: 19278368
[TBL] [Abstract][Full Text] [Related]
7. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Burstein HJ; Somerfield MR; Barton DL; Dorris A; Fallowfield LJ; Jain D; Johnston SRD; Korde LA; Litton JK; Macrae ER; Peterson LL; Vikas P; Yung RL; Rugo HS
J Clin Oncol; 2021 Dec; 39(35):3959-3977. PubMed ID: 34324367
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
9. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.
Rosen LS; Ashurst HL; Chap L
Oncologist; 2010; 15(3):216-35. PubMed ID: 20200040
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in treatment stratification for metastatic breast cancer.
Barton S; Swanton C
Drugs; 2011 Nov; 71(16):2099-113. PubMed ID: 22035512
[TBL] [Abstract][Full Text] [Related]
11. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
12. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
Saxena R; Dwivedi A
Med Res Rev; 2012 Jan; 32(1):166-215. PubMed ID: 22183797
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer: updates and advances in 2016.
Giordano SB; Gradishar W
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):12-17. PubMed ID: 27977463
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs in metastatic breast cancer: an update.
Arslan C; Altundag K; Dizdar O
Expert Opin Emerg Drugs; 2011 Dec; 16(4):647-67. PubMed ID: 22122529
[TBL] [Abstract][Full Text] [Related]
15. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
16. An update on first line therapies for metastatic breast cancer.
Fedele P; Ciccarese M; Surico G; Cinieri S
Expert Opin Pharmacother; 2018 Feb; 19(3):243-252. PubMed ID: 29336185
[TBL] [Abstract][Full Text] [Related]
17. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy of metastatic breast cancer.
Sánchez-Muñoz A; Pérez-Ruiz E; Jiménez B; Ribelles N; Márquez A; García-Ríos I; Alba Conejo E
Clin Transl Oncol; 2009 Oct; 11(10):643-50. PubMed ID: 19828406
[TBL] [Abstract][Full Text] [Related]
20. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]